Source link : https://www.newshealth.biz/health-news/new-bcma-directed-therapies-show-promise-in-multiple-myeloma/
Data presented at the American Society of Hematology (ASH) annual meeting highlighted advances in B-cell maturation antigen (BCMA)-directed therapies, including ABBV-383, a bispecific antibody with reduced toxicity and outpatient potential, and anitocabtagene autoleucel (anito-cel), a CAR-T with high response rates and fewer neurological side effects. MedPage Today brought together three expert leaders in the field: […]
Author : News Health
Publish date : 2024-12-23 16:39:58
Copyright for syndicated content belongs to the linked Source.